Back to Dashboard










AbbVie Inc. (ABBV)
Real-time intraday values
Market Overview
From:
To:
ABBV Intraday
No data available
SymbolABBV
IPO DateJan 2, 2013
CEOMr. Robert A. Michael CPA
Full Time Employees57k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNYSE
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | -1.09% | -2.35 US$ |
| 5 Days | -0.54% | -1.15 US$ |
| 1 Month | +7.37% | +14.64 US$ |
| 6 Months | -6.29% | -14.31 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of ABBV...
Key Statistics
Market Cap
376.95B
P/E Ratio
104.07
Div Yield
321.00%
52W High
$244.81
52W Low
$181.73
Analyst Consensus
CONSENSUSBuy
BULLISH2475.0%
NEUTRAL825.0%
BEARISH00.0%
52W Analyst Price Targets
Min Target
$184.00
$184.00
Max Target
$328.00
$328.00
Current$213.35
Avg Target$252.90
Analyst Recommendations
Precio Objetivo:$252.90($184.00 - $328.00)
Community Thoughts
Share your analysis and sentiment on ABBV
Join the community to share your analysis
Latest News for ABBV
SCHD’s Dividend Quality Filter Now Concentrates 42 Percent of Your Money in Just Ten Stocks
24/7 Wall St.•May 26, 2026, 01:50 PM
3 Stocks Estimated To Be Trading At Discounts Of Up To 44.1%
Simply Wall St.•May 26, 2026, 11:38 AM
Prediction: These 2 Obesity Drug Stocks Could Double in 2026
Motley Fool•May 26, 2026, 08:24 AM
Zifo, Pistoia Alliance, and Pharma Majors Launch Global IVP Assay Repository
PR Newswire•May 26, 2026, 01:00 PM
Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
GlobeNewswire•May 25, 2026, 05:00 PM
Two Paths to Growth: Johnson & Johnson vs AbbVie
24/7 Wall St.•May 25, 2026, 11:47 AM
Three Stocks That May Be Trading Below Their Estimated Value In May 2026
Simply Wall St.•May 25, 2026, 05:38 PM
May 2026's Top Stocks That Could Be Trading Below Estimated Fair Value
Simply Wall St.•May 25, 2026, 11:38 AM
What's the Better Dividend Stock Today: AbbVie or Pfizer?
Motley Fool•May 24, 2026, 04:20 PM
Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV
Motley Fool•May 24, 2026, 10:39 PM